<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804128</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000616972</org_study_id>
    <secondary_id>08755</secondary_id>
    <secondary_id>NCI-2019-07528</secondary_id>
    <secondary_id>R01CA116182</secondary_id>
    <nct_id>NCT00804128</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)</brief_title>
  <official_title>Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose
      ductal carcinoma in situ.

      PURPOSE: This study is to develop and refine magnetic resonance (MR) imaging methods for
      pre-operative staging of ductal carcinoma in situ, a pre-invasive form of breast cancer, and
      atypical ductal hyperplasia, a risk factor for developing cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the DCIS optimized MRI to the standard clinical MRI. Using a scale of 1-5 from
           poor to excellent, images will be assessed for conspicuity of DCIS and atypical ductal
           hyperplasia (ADH) lesions, agreement of disease extent with biopsy, and overall image
           quality (artifact level, uniformity of fat suppression, contrast to noise ratio and
           signal to noise ratio).

        -  Subjects with ADH, a benign condition that can also show enhancement on MRI, will be
           enrolled to explore the utility of the DCIS optimized MRI for distinguishing DCIS and
           ADH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of ductal carcinoma in situ (DCIS)-optimized MRI with standard clinical MRI, in terms of conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of two DCIS-optimized MRIs for variability in enhancement levels for DCIS, in terms of conspicuity of DCIS lesion, agreement of disease extent with biopsy, and overall image quality</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>contrast-enhanced magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadavist</intervention_name>
    <description>Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging</description>
    <other_name>Gadobutrol</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with biopsy proven DCIS Subjects with ADH.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Patient at the University of California, San Francisco Breast Care Center meeting
                  the following criteria:

                    -  Biopsy proven ductal carcinoma in situ (DCIS) of the breast.

                    -  Has undergone mammography within the past 60 days.

                    -  ADH patients: over 18, no prior history of breast disease.

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing (or stopped nursing within the past 3 months)

          -  Negative pregnancy test

          -  No contraindication to MRI (e.g., implanted pacemaker, implanted ferromagnetic device,
             ferromagnetic aneurysm clip, severe claustrophobia, ocular metal fragments, or
             shrapnel injury)

        PRIOR CONCURRENT THERAPY:

          -  More than 2 years since prior surgery to the ipsilateral breast (patient)

          -  No prior radiotherapy to the ipsilateral breast (patient)

          -  No prior cytotoxic regimens (patient)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nola M. Hylton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bonnie Joe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nola Hylton, PhD</last_name>
    <phone>877-827-3222</phone>
    <email>cancertrials@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Watkins</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nola Hylton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

